23 January 2020
Visiongain’s new report the Oncology Companion Diagnostics Market Forecast 2020-2030: Forecasts by Product (Assays, Kits, & Reagents, Software & Technology) By Technology (Polymerase Chain Reaction, In Situ Hybridization, Immunochemistry, Others),by End use (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations, Others) plus analysis of leading companies indicates that the global oncology companion diagnostics market will cross 1.0 billion revenue by 2030.
The benefits of oncology companion diagnostics, the need for targeted treatment, the rising importance of personalized medicine, the increasing global incidence of cancer, and the ever-increasing fields of application of companion diagnostics are driving the growth of the global oncology companion diagnostics industry. The increasing demand for sequencing of the next generation, the rising importance of the companion diagnosis. It is estimated that pharmaceutical & biopharmaceutical companies will account for the largest share of the oncology companion diagnostics market.
Because of their growing popularity in drug development and the importance of oncology companion diagnostic biomarkers, the large share of this segment can be largely attributed to the extensive use of companion diagnostics in these industries. The growing demand for personalized medicine as well as the high demand for specific therapies for different diseases and disorders are also expected to drive the demand and acceptance of companion diagnostics among pharmaceutical and biopharmaceutical companies.
During the forecast period, the oncology companion diagnostic market in the APAC is expected to expand at the highest CAGR. It is expected that the high incidence of cancer, increased proteomics & genomics research, increased research funding, increased investment by pharmaceutical and biotechnology companies and increased awareness of personalized therapy in several APAC countries will drive growth in the APAC market.
Hoffmann-La Roche AG is one of the world's leading suppliers of oncology companion diagnostics. It provides pharmaceutical companies and research institutes with a comprehensive portfolio of companion diagnostic products. Roche is well-established in the companion diagnostics industry with a strong brand name and broad geographical coverage in more than 180 countries.
The company focuses on approaches such as product launches & approvals in order to increase its presence in the companion diagnostics industry. In May 2019, the company launched the diagnostic test VENTANA HER2 Dual ISH companion. This test will provide a tool for Roche CDx customers to detect the HER2 biomarker in breast and gastric cancer, thus assisting pharmaceuticals in the production of personalized medicines and targeted therapies.
Agilent Technologies is yet another major provider of professional diagnostics for pharmaceutical companies, reference laboratories, hospitals, and other accredited medical centers. The company offers comprehensive diagnostic assays & kits where the services are mainly based on the technologies of immunohistochemistry (IHC) and in-situ hybridization (ISH). The company provides end-users with companion diagnostic products through its strong worldwide distribution network. The business strategy of Agilent includes product launches and new therapeutic areas approvals.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth
24 November 2020
Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.